<DOC>
	<DOC>NCT02095860</DOC>
	<brief_summary>The purpose of this study is to assess the effect of a high fat meal and light meal on the blood levels of Daclatasvir, Asunaprevir and BMS-791325 after administration of the 3 drugs as a fixed-dose combination in healthy subjects.</brief_summary>
	<brief_title>Food Effect of a Fixed Dose Combination of Daclatasvir, Asunaprevir and BMS-791325</brief_title>
	<detailed_description>IND Number: 100,932/79,599/101,943 Primary Purpose: Other: Phase 1 clinical pharmacology bioavailability study to assess food effect</detailed_description>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Healthy male and female subjects ages 18 to 49 years, inclusive. Women of childbearing potential must be using an acceptable method of contraception for at least 4 weeks prior to study drug administration. Any significant acute or chronic medical illness Current or recent (within 3 months of study drug administration) gastrointestinal disease Any gastrointestinal surgery that could impact upon the absorption of study drug, including cholecystectomy History of biliary disorders, including Gilbert's syndrome or DubinJohnson disease Use of tobaccocontaining or nicotinecontaining products Any of the following on 12lead electrocardiogram (ECG) prior to study drug administration, confirmed by repeat: PR ≥210 msec QRS ≥120 msec QT ≥500 msec QTcF ≥450 msec Any of the following laboratory results outside of the ranges specified below prior to study drug administration, confirmed by repeat: Alanine aminotransferase (ALT) &gt;Upper limit of normal (ULN) Aspartate aminotransferase (AST) &gt;ULN Total bilirubin (TBILI) &gt;ULN Creatinine &gt;ULN</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>